ResMed COO Robert Andrew Douglas Sells 8,000 Shares (RMD)
ResMed (NYSE:RMD) COO Robert Andrew Douglas sold 8,000 shares of ResMed stock on the open market in a transaction dated Monday, June 2nd. The stock was sold at an average price of $50.11, for a total transaction of $400,880.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of ResMed (NYSE:RMD) traded up 0.90% during mid-day trading on Wednesday, hitting $50.20. 338,233 shares of the company’s stock traded hands. ResMed has a 52-week low of $41.52 and a 52-week high of $57.34. The stock has a 50-day moving average of $49.53 and a 200-day moving average of $46.. The company has a market cap of $7.045 billion and a price-to-earnings ratio of 21.83.
ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $0.63 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter last year, the company posted $0.58 earnings per share. ResMed’s revenue was up 3.7% compared to the same quarter last year. Analysts expect that ResMed will post $2.49 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, June 17th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.99%. The ex-dividend date of this dividend is Friday, May 16th.
A number of analysts have recently weighed in on RMD shares. Analysts at Northland Securities downgraded shares of ResMed from a “market perform” rating to an “underperform” rating in a research note on Tuesday, May 27th. They now have a $40.00 price target on the stock. Separately, analysts at Deutsche Bank upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Thursday, April 24th. They now have a $52.00 price target on the stock. Finally, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of ResMed in a research note on Thursday, April 24th. They now have a $46.08 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $45.90.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.